Press release: Uppsala,
Subscription
The subscription period ended on
Allotment
The allotment of units subscribed for without unit rights has been made in accordance with the terms of the Rights Issue, which are stated in the prospectus. Notification of such allocation will be communicated separately by registered settlement note. Nominee registered shareholders will receive a notice of allocation in accordance with instructions from the respective nominee.
BTU
Trading with BTU (Paid Subscription Unit) takes place on
Share and share capital
Through the Rights Issue, Dicot's share capital will increase by SEK
4,758,557.625 through the issuance of 38,068,461 shares. Following the Rights Issue, and following registration of the Rights Issue with the Swedish Companies Registration Office, the Company's share capital will amount to
Warrants
Through the Rights Issue, the Company also issues 38,068,461 warrants of series 2021/2022, which entitle to subscribe for 38,068,461 shares in the Company.
The warrants of series 2021/2022 that have been issued through the Rights Issue entitle the holder to subscribe for one (1) new share in Dicot during the subscription period from
Upon full exercise of all warrants of series 2021/2022 within the framework of issued units, the Company may receive up to an additional
The warrants are intended to be admitted for trading on
Underwriting commitments
In connection with the Rights Issue, a number of external investors have submitted underwriting commitments. Compensation for such commitment consists of eight (8) percent of the guaranteed amount in cash.
Advisors
For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09
E-mail: goran.beijer@dicot.se
www.dicot.se
About
Dicot is developing the drug candidate LIB-01, which is expected to be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market value has been estimated to approx.
Dicot is listed on
This information is such that
Important information
This press release is not an offer to subscribe for shares, warrants, or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus that Dicot has published on its website on
Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law. Hence, this press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.
There is no intention to apply for approval of any offer to the public in any other country within the European Economic Area ("EES") than Sweden and the securities issued in the Rights Issue will not be offered to the public in these countries.
This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.
https://news.cision.com/dicot-ab--publ-/r/dicot-s-rights-issue-is-subscribed-with-approx--98-percent,c3444981
https://mb.cision.com/Main/17172/3444981/1489811.pdf
(c) 2021 Cision. All rights reserved., source